Marinus Pharmaceuticals, Inc.

BMV:MRNS * Stock Report

Market Cap: Mex$254.8m

Marinus Pharmaceuticals Management

Management criteria checks 2/4

Marinus Pharmaceuticals' CEO is Scott Braunstein, appointed in Aug 2019, has a tenure of 5.33 years. total yearly compensation is $3.21M, comprised of 20.2% salary and 79.8% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth MX$550.03K. The average tenure of the management team and the board of directors is 4.1 years and 3.5 years respectively.

Key information

Scott Braunstein

Chief executive officer

US$3.2m

Total compensation

CEO salary percentage20.2%
CEO tenure5.3yrs
CEO ownership0.2%
Management average tenure4.1yrs
Board average tenure3.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Scott Braunstein's remuneration changed compared to Marinus Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$140m

Jun 30 2024n/an/a

-US$149m

Mar 31 2024n/an/a

-US$145m

Dec 31 2023US$3mUS$650k

-US$141m

Sep 30 2023n/an/a

-US$134m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$35m

Dec 31 2022US$3mUS$591k

-US$20m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$105m

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$4mUS$574k

-US$99m

Sep 30 2021n/an/a

-US$88m

Jun 30 2021n/an/a

-US$84m

Mar 31 2021n/an/a

-US$76m

Dec 31 2020US$4mUS$556k

-US$76m

Sep 30 2020n/an/a

-US$74m

Jun 30 2020n/an/a

-US$72m

Mar 31 2020n/an/a

-US$69m

Dec 31 2019US$2mUS$305k

-US$54m

Sep 30 2019n/an/a

-US$49m

Jun 30 2019n/an/a

-US$46m

Mar 31 2019n/an/a

-US$43m

Dec 31 2018US$210kn/a

-US$37m

Compensation vs Market: Scott's total compensation ($USD3.21M) is above average for companies of similar size in the MX market ($USD187.81K).

Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.

CEO

Scott Braunstein (61 yo)

5.3yrs

Tenure

US$3,214,100

Compensation

Dr. Scott N. Braunstein, M.D., has been the Independent Supervisory Director of Atai Life Science N.V. since May 2024. He serves as an Independent Director at Caribou Biosciences, Inc. since June 2021. He...

Leadership Team

NamePositionTenureCompensationOwnership
Scott Braunstein
CEO, President & Chairman5.3yrsUS$3.21m0.22%
MX$ 550.0k
Steven Pfanstiel
COO, CFO & Treasurer3.7yrsUS$1.44m0.031%
MX$ 79.9k
Joseph Hulihan
Chief Medical Officer5.2yrsUS$1.37m0.031%
MX$ 79.2k
Alex Aimetti
Chief Scientific Officerno datano datano data
Sonya Weigle
Senior VP of Investor Relations1.5yrsno datano data
Martha Manning
Senior VP4.5yrsno data0.022%
MX$ 56.3k
Molly Cameron
Director of Corporate Communications & Investor Relations1.5yrsno datano data
Kimberly McCormick
Chief Regulatory & Quality Assurance Officerno datano datano data
Christina Shafer
Chief Commercial Officer4.1yrsno data0.034%
MX$ 86.7k
David Czekai
Chief Chemistryno datano datano data

4.1yrs

Average Tenure

61yo

Average Age

Experienced Management: MRNS *'s management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Scott Braunstein
CEO, President & Chairman6.3yrsUS$3.21m0.22%
MX$ 550.0k
Timothy Mayleben
Lead Independent Director16yrsUS$202.52k0.025%
MX$ 64.4k
Elan Ezickson
Independent Director5yrsUS$162.52k0.010%
MX$ 25.9k
Jacqueline A. French
Member of Scientific Advisory Boardno datano datano data
Seth H. Fischer
Independent Director8.3yrsUS$160.02k0.011%
MX$ 27.8k
Michael Rogawski
Member of Scientific Advisory Boardno datano datano data
Christine Silverstein
Independent Director1.9yrsUS$249.21kno data
Marvin Johnson
Independent Director1.7yrsUS$304.81k0.0043%
MX$ 11.1k
Eugen Trinka
Member of Scientific Advisory Boardno datano datano data
Elia M. Knight
Member of Scientific Advisory Boardno datano datano data
Rajsekar Rajaraman
Member of the Scientific Advisory Boardless than a yearno datano data
Joseph Sullivan
Member of the Scientific Advisory Boardless than a yearno datano data

3.5yrs

Average Tenure

61yo

Average Age

Experienced Board: MRNS *'s board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:22
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Marinus Pharmaceuticals, Inc. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
François BriseboisCraig-Hallum Capital Group LLC
Jason KolbertD. Boral Capital LLC.